| [1] |
Beckman JA, Schneider PA, Conte MS. Advances in revascularization for peripheral artery disease: Revascularization in PAD[J]. Circ Res, 2021, 128(12):1885-1912.
doi: 10.1161/CIRCRESAHA.121.318261
pmid: 34110904
|
| [2] |
Song P, Rudan D, Zhu Y, et al. Global, regional, and national prevalence and risk factors for peripheral artery disease in 2015: An updated systematic review and analysis[J]. Lancet Glob Health, 2019, 7(8):e1020-e1030.
doi: 10.1016/S2214-109X(19)30255-4
URL
|
| [3] |
Nativel M, Potier L, Alexandre L, et al. Lower extremity arterial disease in patients with diabetes: A contemporary narrative review[J]. Cardiovasc Diabetol, 2018, 17(1):138.
doi: 10.1186/s12933-018-0781-1
pmid: 30352589
|
| [4] |
Pan Y, Luo Y, Hong J, et al. Advances for the treatment of lower extremity arterial disease associated with diabetes mellitus[J]. Front Mol Biosci, 2022, 9: 929718.
doi: 10.3389/fmolb.2022.929718
URL
|
| [5] |
Shamaki GR, Markson F, Soji-Ayoade D, et al. Peripheral Artery Disease: A Comprehensive Updated Review[J]. Curr Probl Cardiol, 2022, 47(11): 101082.
doi: 10.1016/j.cpcardiol.2021.101082
URL
|
| [6] |
Premaratne S, Newman J, Hobbs S, et al. Meta-analysis of direct surgical versus endovascular revascularization for aortoiliac occlusive disease[J]. J Vasc Surg, 2020, 72(2):726-737.
doi: S0741-5214(20)30121-X
pmid: 32171442
|
| [7] |
Rossi M, Iezzi R. Cardiovascular and Interventional Radiological Society of Europe guidelines on endovascular treatment in aortoiliac arterial disease[J]. Cardiovasc Intervent Radiol, 2014, 37(1): 13-25.
doi: 10.1007/s00270-013-0741-9
pmid: 24196266
|
| [8] |
Yang M, Zhang B, Niu G, et al. Long-term results of endovascular reconstruction for aortoiliac occlusive disease[J]. Quant Imaging Med Surg, 2021, 11(4):1303-1312.
doi: 10.21037/qims
URL
|
| [9] |
Çakmak EÖ, Bayam E, Yilmaz F, et al. Midterm outcomes on primary endovascular treatment of 395 aortoiliac occlusive disease patients: A single-center experience[J]. Angiology, 2021, 72(7):640-650.
doi: 10.1177/0003319721991378
pmid: 33541091
|
| [10] |
Tian J, He W, Gao J, et al. Superficial femoral artery calcification is a novel risk factor of microvascular complications in T2DM patients[J]. Calcif Tissue Int, 2020. 106(4): 355-363.
doi: 10.1007/s00223-019-00645-7
|
| [11] |
Al-Zoubi NA, Shatnawi NJ, Bakkar L, et al. Endovascular treatment for critical limb ischemia in type ii diabetes mellitus involving femoropopliteal and infrapopliteal segments: Revascularization strategy[J]. Vasc Health Risk Manag, 2021, 17: 69-76.
doi: 10.2147/VHRM.S298435
pmid: 33692625
|
| [12] |
蔺松若, 唐文贤, 姜伟庆, 等. 药物涂层球囊治疗老年下肢动脉硬化闭塞症经皮穿刺血管腔内成型术术后支架内再狭窄的疗效及安全性[J]. 海南医学, 2022, 33(11):1375-1378.
|
| [13] |
Schneider PA, Laird JR, Tepe G, et al. Treatment Effect of Drug-Coated Balloons Is Durable to 3 Years in the Femoropopliteal Arteries: Long-Term Results of the IN.PACT SFA Randomized Trial[J]. Circ Cardiovasc Interv, 2018, 11(1):e005891.
|
| [14] |
Caradu C, Lakhlifi E, Colacchio EC, et al. Systematic review and updated meta-analysis of the use of drug-coated balloon angioplasty versus plain old balloon angioplasty for femoropopliteal arterial disease[J]. J Vasc Surg, 2019, 70(3):981-995.e10.
doi: S0741-5214(19)30354-4
pmid: 31126769
|
| [15] |
Schmidt A, Piorkowski M, Görner H, et al. Drug-coated balloons for complex femoropopliteal lesions: 2-Year results of a real-world registry[J]. JACC Cardiovasc Interv, 2016, 9(7):715-724.
doi: 10.1016/j.jcin.2015.12.267
URL
|
| [16] |
Gouëffic Y, Torsello G, Zeller T, et al. Efficacy of a drug-eluting stent versus bare metal stents for symptomatic femoropopliteal peripheral artery disease: Primary results of the EMINENT randomized trial[J]. Circulation, 2022, 146(21):1564-1576.
doi: 10.1161/CIRCULATIONAHA.122.059606
pmid: 36254728
|
| [17] |
Bausback Y, Wittig T, Schmidt A, et al. Drug-eluting stent versus drug-coated balloon revascularization in patients with femoropopliteal arterial disease[J]. J Am Coll Cardiol, 2019, 73(6):667-679.
doi: S0735-1097(18)39460-9
pmid: 30765033
|
| [18] |
Phair J, Carnevale M, Lipsitz EC, et al. Primary patency of long-segment femoropopliteal artery lesions in patients with peripheral arterial occlusive disease treated with paclitaxel-eluting technology[J]. Ann Vasc Surg, 2020, 66:595-600.
doi: S0890-5096(19)31045-3
pmid: 31863948
|
| [19] |
王富军, 白磊, 丁海霞, 等. 2型糖尿病下肢血管病变介入治疗362例5年随访分析[J]. 临床荟萃, 2019, 34(8):707-710.
|
| [20] |
Barbarawi M, Qazi AH, Lee J, et al. Meta-analysis comparing drug-coated balloons and percutaneous transluminal angioplasty for infrapopliteal artery disease[J]. Am J Cardiol, 2022, 183:115-121.
doi: 10.1016/j.amjcard.2022.08.007
pmid: 36116953
|
| [21] |
Jia X, Zhuang B, Wang F, et al. Drug-coated balloon angioplasty compared with uncoated balloons in the treatment of infrapopliteal artery lesions (acoart II-BTK)[J]. J Endovasc Ther, 2021, 28(2):215-221.
doi: 10.1177/1526602820969681
pmid: 33118432
|
| [22] |
鞠上, 杨博华, 林冬阳, 等. 膝下动脉腔内成形术治疗重症糖尿病肢体血管病变[J]. 疑难病杂志, 2008, 7(07):394-396.
|
| [23] |
Liistro F, Angioli P, Ventoruzzo G, et al. Randomized controlled trial of acotec drug-eluting balloon versus plain balloon for below-the-knee angioplasty[J]. JACC Cardiovasc Interv, 2020, 13(19):2277-2286.
doi: 10.1016/j.jcin.2020.06.045
URL
|
| [24] |
Katsanos K, Kitrou P, Spiliopoulos S, et al. Comparative effectiveness of plain balloon angioplasty, bare metal stents, drug-coated balloons, and drug-eluting stents for the treatment of infrapopliteal artery disease: Systematic review and bayesian network meta-analysis of randomized controlled trials[J]. J Endovasc Ther, 2016, 23(6):851-863.
pmid: 27708143
|
| [25] |
Matsuoka EK, Hasebe T, Ishii R, et al. Comparative performance analysis of interventional devices for the treatment of ischemic disease in below-the-knee lesions: A systematic review and meta-analysis[J]. Cardiovasc Interv Ther, 2022, 37(1):145-157.
doi: 10.1007/s12928-021-00758-7
|
| [26] |
Siablis D, Kitrou PM, Spiliopoulos S, et al. Paclitaxel-coated balloon angioplasty versus drug-eluting stenting for the treatment of infrapopliteal long-segment arterial occlusive disease: the IDEAS randomized controlled trial[J]. JACC Cardiovasc Interv, 2014, 7(9):1048-1056.
doi: 10.1016/j.jcin.2014.04.015
URL
|
| [27] |
杨永久, 丁旭, 满新贺, 等. 膝下动脉药物球囊扩张成形术治疗严重下肢缺血的单中心临床分析[J]. 中国医刊, 2020, 55(11):1226-1229.
|
| [28] |
Farber A, Menard MT, Conte MS, et al. Surgery or endovascular therapy for chronic limb-threatening ischemia[J]. N Engl J Med, 2022, 387(25): 2305-2316.
doi: 10.1056/NEJMoa2207899
URL
|
| [29] |
Amlani V, Falkenberg M, Nordanstig J. The current status of drug-coated devices in lower extremity peripheral artery disease interventions[J]. Prog Cardiovasc Dis, 2021, 65: 23-28.
doi: 10.1016/j.pcad.2021.02.002
URL
|
)
